This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Urteste enrolls first Panuri patient
Tech clinical study enrollment

Urteste enrolls first Panuri patient

Analysis based on 7 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The enrollment of the first patient in the Panuri test clinical study by Urteste is a positive development for the company, potentially leading to increased investor confidence and a rise in its stock price. Successful interim analysis results could further boost the likelihood of partnership agreements, directly impacting Urteste's market valuation and attracting strategic partners.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Urteste, a company specializing in cancer detection technology, has enrolled the first patient in the clinical study for its Panuri test, designed for non-invasive pancreatic cancer detection using urine samples. This multicenter study is being conducted in Poland, Hungary, and Italy, involving 30 centers and 550 participants. The company expects interim analysis results by the fourth quarter of 2026. This milestone significantly reduces risks associated with the preparatory phase and moves the Panuri test closer to commercialization. Urteste is collaborating with Aurevia for CRO services and Biotype for CDMO services. Positive results from this study are anticipated to increase the likelihood of partnership agreements and will be crucial for the IVD medical device certification in Europe, with potential to supplement data for a planned study in the United States. The Panuri test is a priority project for Urteste, which also has 13 other diagnostic test prototypes for various cancers.

Entities Involved
stock
Urteste
Urteste has enrolled the first patient in its Panuri test clinical study, marking a significant step towards commercialization and potentially increasing its value through future partnership agreements and market certification.
Importance 100.0 Sentiment 70.0
oth
Panuri test
The Panuri test is Urteste's priority project, a non-invasive diagnostic test for pancreatic cancer, which has entered its active clinical study phase.
Importance 90.0 Sentiment 65.0
per
Grzegorz Stefański
Grzegorz Stefański, co-founder and CEO of Urteste, provides commentary on the significance of the Panuri test's progress and its potential for early pancreatic cancer detection.
Importance 70.0 Sentiment 60.0
oth
Aurevia
Aurevia, a Finnish group, is conducting the clinical study for the Panuri test as a Contract Research Organization (CRO).
Importance 40.0 Sentiment 50.0
oth
Biotype
Biotype, a German company, is responsible for the production of the Panuri test as a Contract Development and Manufacturing Organization (CDMO).
Importance 40.0 Sentiment 50.0
cnt
Hungary
Hungary is one of the countries where the multicenter clinical study for the Panuri test is being conducted.
Importance 30.0 Sentiment 0.0
cnt
Poland
Poland is one of the countries where the multicenter clinical study for the Panuri test is being conducted.
Importance 30.0 Sentiment 0.0
cnt
Italy
Italy is one of the countries where the multicenter clinical study for the Panuri test is being conducted.
Importance 30.0 Sentiment 0.0
cnt
United States
The clinical data from the current study may supplement data for a planned study in the United States for the Panuri test.
Importance 20.0 Sentiment 0.0
loc
Europe
The study results will be used for the certification process of the IVD medical device in Europe.
Importance 20.0 Sentiment 0.0
Relationships
Hungary related ↔ Poland
Hungary related ↔ Italy
Hungary related ↔ United States
Poland related ↔ Italy
Poland related ↔ United States
Italy related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.